Aims Heart failure (HF) pathophysiology is believed to be mediated by autonomic dysfunction, including chronic sympathoexcitation and diminished baroreflex sensitivity, which correlate with mortality risk. Baroreflex activation therapy (BAT) is a device-based treatment providing chronic baroreflex activation through electrical stimulation of the carotid sinus. BAT chronically reduces sympathetic activity in resistant hypertension. The purpose of this investigation is to determine BAT effects in clinical HF.and results In a single-centre, open-label evaluation, patients with NYHA class III HF, EF <40%, optimized medical therapy, and ineligible for cardiac resynchronization received BAT for 6 months. Efficacy was assessed with serial measurement of muscle sympathetic nerve activity (MSNA) and clinical measures of quality of life and functional capacity. Eleven patients participated in the trial. MSNA was reduced over 6 months from 45.1±7.7 to 31.3±8.3 bursts/min and from 67.6±12.7 to 45....

Gronda, E., Seravalle, G., Brambilla, G., Costantino, G., Casini, A., Alsheraei, A., et al. (2014). Chronic baroreflex activation effects on sympathetic nerve traffic, baroreflex function, and cardiac haemodynamics in heart failure: a proof-of-concept study. EUROPEAN JOURNAL OF HEART FAILURE, 16(9), 977-983 [10.1002/ejhf.138].

Chronic baroreflex activation effects on sympathetic nerve traffic, baroreflex function, and cardiac haemodynamics in heart failure: a proof-of-concept study

BRAMBILLA, GIANMARIA;COSTANTINO, GIUSEPPE;MANCIA, GIUSEPPE;GRASSI, GUIDO
2014

Abstract

Aims Heart failure (HF) pathophysiology is believed to be mediated by autonomic dysfunction, including chronic sympathoexcitation and diminished baroreflex sensitivity, which correlate with mortality risk. Baroreflex activation therapy (BAT) is a device-based treatment providing chronic baroreflex activation through electrical stimulation of the carotid sinus. BAT chronically reduces sympathetic activity in resistant hypertension. The purpose of this investigation is to determine BAT effects in clinical HF.and results In a single-centre, open-label evaluation, patients with NYHA class III HF, EF <40%, optimized medical therapy, and ineligible for cardiac resynchronization received BAT for 6 months. Efficacy was assessed with serial measurement of muscle sympathetic nerve activity (MSNA) and clinical measures of quality of life and functional capacity. Eleven patients participated in the trial. MSNA was reduced over 6 months from 45.1±7.7 to 31.3±8.3 bursts/min and from 67.6±12.7 to 45....
Articolo in rivista - Articolo scientifico
Baroreflex; Heart failure; Non-pharmacological therapy; Sympathetic nervous system;
Baroreflex; Heart failure; Non-pharmacological therapy; Sympathetic nervous system
English
2014
16
9
977
983
none
Gronda, E., Seravalle, G., Brambilla, G., Costantino, G., Casini, A., Alsheraei, A., et al. (2014). Chronic baroreflex activation effects on sympathetic nerve traffic, baroreflex function, and cardiac haemodynamics in heart failure: a proof-of-concept study. EUROPEAN JOURNAL OF HEART FAILURE, 16(9), 977-983 [10.1002/ejhf.138].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/56965
Citazioni
  • Scopus 157
  • ???jsp.display-item.citation.isi??? 137
Social impact